Read More: https://www.tipranks.com/news/blurbs/immutep-ltd-prruf-receives-a-buy-from-wilsons?utm_source=alphanewsstream.com&utm_medium=referral
Immutep Ltd (PRRUF) was recommended to buy by Wilsons. Read More »
Read More: https://www.tipranks.com/news/company-announcements/immutep-ltd-announces-a100m-capital-raising-effort?utm_source=alphanewsstream.com&utm_medium=referral
Immutep Ltd is announcing a fundraising effort of A$100 million. Read More »
Read More: https://www.tipranks.com/news/company-announcements/immutep-ltd-announces-a100m-capital-raising-effort?utm_source=alphanewsstream.com&utm_medium=referral
– Immutep Ltd reveals plans for a A$100 million fundraising initiative. Read More »
Read More: https://www.tipranks.com/news/company-announcements/immutep-limited-plans-major-securities-issuance?utm_source=alphanewsstream.com&utm_medium=referral
Immutep Limited is planning a significant securities issuance. Read More »
Phase III collaboration will assess the effectiveness of efti in combination with KEYTRUDA, MSD’s anti-PD-1 therapy, and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC)TACTI-004 Phase III…
Phase III collaboration will assess efti with KEYTRUDA and standard chemotherapy in first-line non-small cell lung cancer (1L NSCLC) as part of the TACTI-004 Phase III study.
Stay updated with the latests analysis and insights fromm etfsector.com
